Abstract
Introduction
Electroconvulsive therapy (ECT) is an effective and safe treatment option for specific forms of depression, such as treatment-resistant depression, psychotic depression or melancholia in both uni-and bipolar affective disorder [1, 2] with response rates usually ranging around 70%. Despite this remarkable efficacy even in highly treatment-resistant depression, there is still a considerable group of non-responders to ECT. Therefore, it is of high clinical interest to identify factors or markers that could provide information prior to treatment on whether the individual patient will respond to ECT or not.
Previous studies have provided a large body of evidence about potentially prognostic demographic or clinical factors such as age, bipolarity, severity of the current episode, family history of depression or comorbid axis II disorder that might contribute to the risk of non-response to ECT [3, 4] . Others tried to elucidate whether a set of ictal parameters might predict the clinical outcome [5, 6] . More recently, different imaging markers have been suggested to predict the outcome to ECT in major depression, for example, the baseline level of higher BOLD signal fluctuations of the subcallosal cingulate cortex [7] , the subgenual cingulate volume [8] and several grey matter regions [9] , but further studies are needed to reach a consensus on which the brain region shows the best performance.
A few blood-based candidate biomarkers have been identified as prognostic factors in patients treated with ECT, including vascular endothelial growth factor [10] and homovanillic acid [11] . In contrast to markers from blood that might not be central nervous system-specific, markers measured in the cerebrospinal fluid (CSF) are able to reflect cerebral processes much more directly. However, CSF biomarkers predicting outcome to ECT in patients with major depression have not been identified yet.
We recently conducted a study in which CSF samples before and after a course of ECT in patients with severe depression were collected [12] [13] [14] [15] [16] . In that study, we aimed to evaluated different systems that might contribute to either the antidepressant action of ECT or unspecific effects of ECT. Such systems were the innate immune system, which is known to contribute in a complex and yet not completely unravelled way to the pathogenesis of depression and to antidepressant action [17, 18] . On the other hand, we analysed different systems, such as the endocannabinoid system [19, 20] , sphingolipids [21] and the hormone Klotho [22, 23] , all, which have been just recently linked to depression. Additionally, we analysed markers of neurodegeneration, which are mainly associated to Alzheimer's disease (AD) but have also shown to be associated with depression [24] [25] [26] .
In this recent study, we analysed all these biomarkers in patients with depression to identify possible correlations of their baseline CSF levels before ECT with the clinical response to ECT in an exploratory approach.
Methods

Patients
Our study was approved by the appropriate Ethics Committee and was performed in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki). Written informed consent was obtained from all participants before enrolment. The study took place from 2012 to 2014 at the Department of Psychiatry at the Central Institute of Mental Health in Mannheim, Germany. Inclusion criteria were (i) a present treatment resistant depressive episode (defined as failure to achieve response or remission to at least 2 proven antidepressant trial with adequate dosing and duration [27] ) within the context of a diagnosis of either major depressive disorder or bipolar disorder according to DSM-IV, (ii) age above 18 years and (iii) the clinical decision for an ECT treatment. Exclusion criteria were (i) substance-related disorders including tobacco and alcohol, (ii) the lifetime diagnosis of schizophrenia, (iii) any signs of an ongoing inflammatory process such as leucocytosis, elevated acute phase proteins or fever, (iv) the intake of any medication with known immunomodulatory properties such as non-steroidal anti-inflammatory drugs or glucocorticoids, and (v) the reported use of Δ9-tetrahydrocannabinol 12 months before the study or detection of Δ9-tetrahydrocannabinol in urine drug screen. The patients continued their prior psychotropic medication during the ECT treatment. The Hamilton Depression Rating Scale (HDRS; 21 items version) was used to assess the severity of depression before and after the ECT in each patient. Response was defined as a reduction of at least 50% in symptoms measured by the HDRS. The Mini-Mental-State Examination (MMSE) was used to assess the gross cognitive performance prior to treatment. ECT Treatment Right unilateral brief pulse ECT was performed with a Thymatron IV device (Somatics, LLC, Lake Bluff, IL, USA), s-ketamine was used as the anaesthetic substance (∼1.0 mg/kg) [28, 29] and succinylcholine for muscle relaxation (∼1.0 mg/kg). Seizure threshold in all patients was titrated at the initial session and dosing at subsequent treatments was given at > 2.5 times above threshold. Mean charge administered was 60.1 ± 39.8 mC. The energy was subsequently increased if patients did not respond clinically or if seizures were insufficient during the ECT course. Two or three ECT sessions per week were performed. All patients started with unilateral stimulation, and in the case of non-response, it was possible to switch to bilateral stimulation as a decision of the ECT supervisor.
Sampling
Before the first ECT session, all CSF samples were drawn at around 9: 00 a.m. The patients were in a non-fasting status. They had a light breakfast at 8: 00 a.m. because ECT was administered in the afternoon. Lumbar punctures were performed in the sitting position according to standardized procedure. Samples were then aliquoted and transferred at -80 ° C within 30 min either in glass vials (Hycultec, Beutelsbach, Germany) for the analyses of the lipids, in polypropylene tubes for the analyses of the markers of neurodegeneration or in protein LoBind tubes (Eppendorf, Germany) for all other substances. The samples were stored at -80 ° C and were never thawed or refrozen prior to the presented analyses.
CSF and Serum Laboratory Analyses
For each analysis, all samples were analysed on one occasion on the same plates using the same batch of reagents.
Elements of the Innate Immune System CSF concentrations were measured as instructed by the manufacturer, using sandwich enzyme-linked immunosorbent assay (ELISA) kits for interleukin (IL)-6, neopterin, soluble CD14 (sCD14), soluble CD163 (sCD163), macrophage migration inhibitory factor (MIF) and monocyte chemotactic protein 1 (MCP-1) as described elsewhere [14] .
Tau Proteins and β-Amyloids All samples were measured at the National Transmissible Spongiform Encephalopathies Reference Centre (Göttingen, Germany). CSF levels of Aβ1-40, Aβ1-42, total tau (T-tau) and its phosphorylated isoform (P-tau) were determined with commercially available ELISA kits, described elsewhere [16] . Neurogranin All samples were measured at the Clinical Neurochemistry Laboratory at Sahlgrenska University Hospital. CSF Ng concentration was measured by ELISA, essentially as described [30] , using the anti-Ng antibody pair Ng2 and Ng22. Intra-assay coefficients of variation were below 10%.
Endocannabinoids
All samples were measured at the Lipidomics/Mass Spectrometry Facility at the Institute of Physiological Chemistry at the University Medical Center of the JGU Mainz. Endocannabinoids were qualitatively and quantitatively analysed using liquid chromatography/multiple reaction monitoring according to the procedures described elsewhere [31, 32] . Levels of both N-arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol (2-AG) were measured, as well as levels of arachidonic acid, which is both a metabolite of endocannabinoids and a substrate for their synthesis. Phospholipids Phosphatidylcholines, ceramides and sphingomyelin analyses were performed on a QTRAP5500 (ABSciex) coupled to a Triversa NanoMate device (Advion) as previously described [33] . sKlotho All samples were measured at the Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Hannover, Germany. The concentration of Klotho in CSF was quantified using a human Klotho ELISA kit measuring the entire soluble α-Klotho protein secreted in the systemic circulation after its release from the cell membrane via shedding (cleaved Klotho) or alternative splicing (secreted Klotho; Immuno-Biological Laboratories Co., Ltd., Gunma, Japan).
Statistical Analyses
Statistics were performed using STATA ® version 11 (StataCorp, TX 77845, USA) at a significance level ≤0.05. Normality was examined using the Shapiro-Wilk and data were log-transformed when necessary. No correction for multiple testing was performed to avoid type II errors in this study with its small sample size. In line with that, results with significance levels between 0.05 and 0.1 were additionally reported as trend observations. Spearman's correlation (rs) was used to determine the strength and direction of the relationship between the concentration of the different markers and the reduction of depressive symptoms during ECT or possible moderators. Linear regression was used to estimate which single marker could predict the reduction of the HDRS score during ECT and multiple regression analysis with stepwise inclusion was used to identify models, in which more than one marker could add significantly to the prediction. Group differences between responders and non-responders were examined with the Wilcoxon rank-sum test. A logistic regression (responder vs. non-responder) was not possible due to the small sample size. In the case of values below the level of detection, it was decided to substitute them with level of detection/2, although we are aware of the potential bias and imprecision [34] .
Results
We included 12 patients into the study, who completed a course of ECT and underwent lumbar puncture prior to ECT. In general, ECT was effective with a reduction of the mean initial HDRS from 29.9 ± 6.6 to 9.0 ± 5.2 after the final session (p < 0.001). Ten patients (83.3%) were classified as treatment responders, whereas 2 patients (16.7%) were considered non-responders to ECT. Three patients (2 females, one male, mean age: 75.7 ± 6.4) had a clinical diagnosis of an AD in addition to their current severe depressive episode. Demographic and clinical features are shown in Tables 1 and 2. For the markers of neurodegeneration (T-tau, P-tau, Aβ1-40, Aβ1-42, Ng) the samples of all 12 patients could be measured. For the immunologic parameters IL-6, neopterin, sCD14, sCD163, migration inhibitory factor, monocyte chemotactic protein 1 and the endocannabinoids 11 samples were measured, whereas for the analysis of Klotho only 8 samples were still available. The analysis for the sphingolipids was performed with 10 samples.
Absolute Reduction of Depressive Symptoms
Baseline CSF levels of AEA (rs = 0.65; p = 0.029), Aβ1-40 (rs = 0.64; p = 0.025), T-tau protein (rs = 0.68; p = 0.015) and P-tau (rs = 0.58; p = 0.049), Ng (rs = 0.64; p = 0.024), sCD14 (rs = 0.82; p = 0.0021) positively correlated with the absolute reduction of depressive symptoms during ECT ( Fig. 1-3) . At the trend level, we found this correlation also for CSF levels of IL-6 (rs = 0.56; p = 0.072), neopterin (rs = 0.54; p = 0.087), sCD163 (rs = 0.54; p = 0.084), phos- phatidylcholines (rs = 0.58; p = 0.080) and the total amount of sphingolipids (rs = 0.58; p = 0.080). Age (p = 0.79), MMSE at baseline (p = 0.39), clinical AD diagnosis (p = 0.12) and sex (p = 0.44) were not associated with the reduction of depressive symptoms during ECT. A summary of the significant findings is presented in Table 3 . Linear regression models established that the baseline levels of all sCD14 (F(1, 9) = 18.91; p = 0.002) , T-tau (F(1, 10) = 9.3; p = 0.013) and P-tau (F(1, 10) = 9.49; p = 0.012) are able to statistically significantly predict the absolute reduction of depressive symptoms.
Relative Reduction of Depressive Symptoms
Correlations with the relative reduction of depressive symptoms (i.e., HDRS-score reduction in percentage) during ECT were found only for the baseline levels of sCD14 (rs = 0.65; p = 0.032). We found no correlation with potential confounders such as age (p = 0.51), MMSE at baseline (p = 0.49) or the clinical AD diagnosis (p = 0.33). At the trend level, women had a higher relative HDRS reduction by ECT than men (p = 0.057).
Responders vs. Non-Responder
We found a difference in the baseline CSF levels in responders compared to those patients who did not show a response to the treatment for neurogranin (137.2 vs. 20.0 pg/mL; z = 2.0; p = 0.024) and P-tau (39.2 vs. 15.0 pg/mL; z = 2.0; p = 0.016) and at the trend level of significance for T-tau protein (301.8 vs. 133.5 pg/mL; z = 1.7; p = 0.054) and sCD163 (2,703.2 vs. 1,247.8 pg/mL; z = 1.7; p = 0.095). Age (p = 0.39), MMSE at baseline (p = 1.00), the clinical AD diagnosis (p = 0.42) or sex (p = 0.33) were not associated with the outcome parameter "response to ECT," defined as a reduction of at least 50% in symptoms measured by the HDRS. 
Correlation with Confounders
We found group differences concerning baseline CSF levels of several markers between the group of patients without and with the clinical diagnosis of AD: AEA (0.76 vs. 1.77 pg/mL; t = 2.3; p = 0.045), T-tau protein (233.1 vs. 395.7 pg/mL, t = 2.4; p = 0.038), Aβ1-40 (9,208.7 vs. 16,267.3 pg/mL, t = 1.9; p = 0.082), IL-6 (2.3 vs. 6.8 pg/ mL; t = 3.2; p = 0.011), neopterin (1.1 vs. 1.9 ng/mL; t = 2.4; p = 0.043), sCD14 (57.4 vs. 78.3 ng/mL; t = 2.8; p = 0.020), sCD163 (1,864.0 vs. 3,970.8 pg/mL; t = 3.8; p = 0.0040), phosphatidylcholines (2.9 vs. 4.3 ng/mL; t = 3.2; p = 0.012) and the total amount of sphingolipids (3.9 vs. 5.7 ng/mL; t = 3.6; p = 0.0074). Only two correlations were detected for the confounding factor "age": sCD14 (rs = 0.61); p = 0.048) and sCD163 (rs = 0.60); p = 0.053). For the variable "sex," we did not find any correlation with those markers.
We found no difference in the clinical outcome or any of the CSF markers between the group of patients who had antidepressants, antipsychotics and lithium, and those who did not take antidepressants, antipsychotics and lithium (data not shown).
Discussion
This is the first study that investigated the antidepressant outcome of ECT based on biomarker profiles in CSF at baseline, which could be a clinically useful approach for future applications of biomarkers. We found a variety of markers from different research areas that were correlated with absolute and relative reduction of the HDRS that could be observed during a course of ECT or with the status responders vs. non-responders to ECT. Markers of neuro- degeneration and of the innate immune system were those that correlated the most with the antidepressant efficacy.
In terms of neurodegeneration, CSF levels of T-tau, Ptau, Aβ1-40 and neurogranin, all known to be highly correlated or associated with each other also in patients without overt neurodegeneration [35] . Were correlated with any form of therapeutic effect, independent of confounders such as age or the presence of a clinical diagnosis of AD. A similar relationship between those markers and response to any antidepressant efficacy has not been reported yet and should be investigated in more detail in future studies.
Based on the relative abundance on the relationship between the immune system and different aspects of depression [36] [37] [38] , it is not surprising that the baseline CSF levels of sCD14 and to a lesser extent of IL-6, neopterin and sCD163 -all involved primarily in the innate immune response [14] , were positively correlated with the antidepressant outcome of ECT, but this underlines the importance of understanding these interactions.
Interestingly, neurodegeneration and the immune system are closely associated with each other and with depression itself: Changes of tau proteins and Aβ within AD are known to be associated with inflammation [39] , whereas inflammation and immune responses are linked to the pathophysiology of depression via the kynurenine pathway [40] [41] [42] and inflammation is seen in both depression and AD with dysfunctional Aβ and tau proteins [43] . Our findings point towards an involvement of these complex systems in the antidepressant mechanism of ECT. To unambiguously assign and include these modes to the established pathomechanisms of ECT, this involvement has to be explored in a more detailed way.
For the lipid markers, the initial CSF levels of the endocannabinoid AEA and of elements of the sphingolipids were associated with antidepressant efficacy during ECT. Those markers have not been investigated concerning the antidepressant outcome prediction yet, but at least our group recently reported that CSF AEA levels are increased by ECT and that those levels were positively correlated with the number of ECT session that were performed in each individual patient [13] . This finding corroborates with a growing body of -primarily preclinical -evidence that suggests an involvement of the endocannabinoid system in the pathophysiology of depression [44] ; hence, more studies are required to elucidate the relationship between depression/antidepressant action and the endocannabinoid system in human. Sphingolipids, especially ceramides, have already been linked with depression [21, 45] ; thus, the results at a trend level significance could be cautiously integrated into this concept.
Limitations
The major limitation of our study is probably the small sample size that makes outliers and an uneven distribution of the dichotomous response/non-response outcome even more problematic. For the enrolment in the original study [12, [14] [15] [16] 32] , patients had to consent to lumbar puncture twice -before and after ECT; therefore, the recruitment of study subjects was difficult. Nevertheless, the sample size was large enough to identify larger effects and at least suggesting some more moderate effects as well. Thus, these positive results from our small sample group are promising to be replicated in future studies. Surely, we cannot exclude that with a larger sample size, smaller effects of certain markers could have been unveiled. A further limitation is that based on the clinical reality, the study was only possible to conduct with our patients continuing some of their psychotropic medication that consisted of antidepressants, antipsychotics and lithium during the ECT treatment. In our cases, the medication in each patient was invariably kept constant during the ECT course. Another limitation is that 3 patients with a comorbid AD were included into the analysis. Indeed, it could be shown that even in our small sample, several group differences could be observed. However, both the clinical AD diagnosis and the MMSE at baseline were no relevant confounding factors for the outcome parameters. Due to the design of our study, it is not possible to unmask any causal relationship between ECT and the identified CSF markers that correlated with the antidepressant efficacy.
In summary, our CSF study was primarily meant to identify markers that indicate whether the therapy option of ECT in patients with severe depression might be successful. We are well aware, that our data must be seen as very preliminary and that the results can only act as a stimulus for further research regarding the mechanism of ECT and personalized antidepressant therapy.
